Septerna, Inc.(SEPN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SEPN Septerna, Inc.

盘后交易 08-25 18:19:37 EDT

41.30

+0.78

+1.92%

盘后40.48

-0.82-1.99%

17:11 EDT

最高41.85	最低40.47	成交量33.32万
今开41.57	昨收40.52	日振幅3.41%
总市值19.28亿	流通市值9.46亿	总股本4,668万
成交额1,376万	换手率1.46%	流通股本2,290万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":41.3,"timestamp":1787688000000,"preClose":40.52,"halted":0,"volume":333224,"hourTrading":{"tag":"盘后","latestPrice":40.48,"preClose":41.3,"latestTime":"17:11 EDT","volume":2006,"amount":82846.97754,"timestamp":1787692284071,"change":-0.82,"changeRate":-0.019855,"amplitude":0.019855},"delay":0,"changeRate":0.01924975320829205,"floatShares":22896300,"shares":46676947,"eps":-0.542426,"marketStatus":"盘后交易","change":0.78,"latestTime":"08-25 18:19:37 EDT","open":41.57,"high":41.85,"low":40.47,"amount":13759204.500168,"amplitude":0.034057,"askPrice":41.31,"askSize":133,"bidPrice":40.47,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.542426,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":40.52,"preHourTrading":{"tag":"盘前","latestPrice":41,"preClose":40.52,"latestTime":"09:28 EDT","volume":6,"amount":245.41997999999998,"timestamp":1787664480044,"change":0.48,"changeRate":0.011846,"amplitude":0.01382},"postHourTrading":{"tag":"盘后","latestPrice":40.48,"preClose":41.3,"latestTime":"17:11 EDT","volume":2006,"amount":82846.97754,"timestamp":1787692284071,"change":-0.82,"changeRate":-0.019855,"amplitude":0.019855},"volumeRatio":0.851466,"impliedVol":1.0749,"impliedVolPercentile":0.9761},"requestUrl":"/m/hq/s/SEPN/wiki","defaultTab":"wiki","newsList":[{"id":"1164246465","title":"新闻稿：Septerna任命资深行业专家Rajiv Patni医学博士担任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1164246465","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164246465?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:05","pubTimestamp":1787659519,"startTime":"0","endTime":"0","summary":"南旧金山，2026年8月25日——Septerna, Inc.，一家致力于开创G蛋白偶联受体药物发现新纪元的临床阶段生物技术公司，今日宣布任命Rajiv Patni医学博士为首席医疗官。Patni博士是一位兼具医师与科学家身份的生物制药高管，拥有超过25年领导研发、监管及医学事务组织的丰富经验。“在我的职业生涯中，我多次在研发轨迹的转折点加入公司，而Septerna正处在这一阶段，”Patni博士表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4599","GPCR","SEPN","R","BK4232","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102039415","title":"Septerna启动口服小分子PTH1R激动剂SEP-479治疗甲状旁腺功能减退症的I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1102039415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102039415?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:06","pubTimestamp":1776081995,"startTime":"0","endTime":"0","summary":"Septerna公司宣布，已正式启动SEP-479的I期临床试验。该药物是一种口服小分子PTH1R激动剂，旨在治疗甲状旁腺功能减退症。这一进展标志着Septerna在代谢性疾病治疗领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184626731","title":"Septerna公布口服Mrgprx2激动剂SEP-631治疗肥大细胞驱动疾病的积极1期数据，并公布初步2期开发战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1184626731","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184626731?lang=zh_cn&edition=full","pubTime":"2026-03-01 22:50","pubTimestamp":1772376629,"startTime":"0","endTime":"0","summary":"生物技术公司Septerna宣布其口服Mrgprx2靶向药物SEP-631在治疗肥大细胞驱动疾病的1期临床试验中获得积极数据。该药物展现出良好的安全性和耐受性特征，为后续临床开发奠定基础。公司同时公布了针对该候选药物的初步2期临床试验战略规划，标志着其向解决免疫炎症疾病迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614814415","title":"Septerna, Inc.盘中异动 快速下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614814415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614814415?lang=zh_cn&edition=full","pubTime":"2026-02-28 02:21","pubTimestamp":1772216510,"startTime":"0","endTime":"0","summary":"北京时间2026年02月28日02时21分，Septerna, Inc.股票出现异动，股价急速下跌5.05%。Septerna, Inc.股票所在的生物技术行业中，整体涨幅为0.97%。Septerna, Inc.公司简介：Septerna Inc是一家临床阶段的生物技术公司，开创了G蛋白偶联受体口服小分子药物发现的新时代，该公司拥有专有的Native Complex Platform。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022802215097a75b0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022802215097a75b0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512111982","title":"富国银行：下调Septerna(SEPN.US)评级，由增持调整至持股观望评级, 目标价由43.00美元调整至14.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512111982","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512111982?lang=zh_cn&edition=full","pubTime":"2025-02-19 07:19","pubTimestamp":1739920740,"startTime":"0","endTime":"0","summary":"富国银行：下调Septerna(SEPN.US)评级，由增持调整至持股观望评级, 目标价由43.00美元调整至14.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19071948243653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元，医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来，生物医药领域已经有30家公司IPO上市，累计融资规模超40.49亿美元，其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域，阿斯利康以总价18亿美元收购AmolytPharma，获得了处于临床3期的PTH1R激动剂eneboparatide，目前该疗法已经获得了FDA快速通道认定，另一家药企AscendisPharma的Yorvipath获得FDA批准上市，用于治疗成人慢性甲状旁腺功能减退。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4200","BK4007","BK4082","PSQ","NQmain","SYRS","AVTE","QLD","BDMD","TSLP","MNQmain","BK4139","OMGA","BK4539","BK4020","UPB","APGE","TQQQ","GPCR","SQQQ",".IXIC","CAMP","BK4599","GLYC","QID","SEPN","ASO","BK4561"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2478942409","title":"生物技术公司Septerna纳斯达克上市：市值8.8亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2478942409","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2478942409?lang=zh_cn&edition=full","pubTime":"2024-10-26 17:00","pubTimestamp":1729933237,"startTime":"0","endTime":"0","summary":"生物技术公司Septerna(股票代码：SEPN）昨日在美国纳斯达克上市，发行价为18美元，募资总额为2.88亿美元。Septerna开盘价为23.5美元，较发行价上涨30.6%；收盘价为21.4美元，较发行价上涨18.89%；以收盘价计算，公司市值为8.83亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241026/6386555882527650514751001.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241026/6386555882527650514751001.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n28045/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["ARTL","NQmain",".IXIC","PPT","QLD","SEPN","BK1147","MNQmain","QID","TQQQ","SQQQ","PSQ","03086","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1104852603","title":"异动解读 | 生物技术公司Septerna大涨30%:IPO披露规模上调引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1104852603","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104852603?lang=zh_cn&edition=full","pubTime":"2024-10-26 00:10","pubTimestamp":1729872621,"startTime":"0","endTime":"0","summary":"针对整个GPCR类药物开发的生物技术公司Septerna周四在纳斯达克资本市场上市价格暴涨超30%,引发市场关注。这与公司日前提高了预期IPO发行规模密切相关。Septerna成立于2019年,专注于开发针对整个GPCR药物类的新型口服小分子药物。作为Septerna的主要及唯一临床阶段项目,治疗甲状旁腺功能减退症的SEP-786将于2025年中期获得关键临床试验数据。公司在GPCR药物开发领域的深耕及项目进展,体现出其作为行业先锚的地位和巨大成长潜力,因此在IPO过程中获得市场热捧并非偶然。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 生物技术公司Septerna大涨30%:IPO披露规模上调引关注","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478671575","title":"GPCR药物开发商Septerna(SEPN.US)IPO规模上调57% 定价18美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2478671575","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2478671575?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:44","pubTimestamp":1729842267,"startTime":"0","endTime":"0","summary":"智通财经获悉，生物技术公司Septerna周四提高了其即将进行的首次公开募股的拟议交易规模。该公司目前计划以每股18美元的价格发行1530万股股票，以筹资2.75亿美元。据悉，Septerna成立于2019年，专注于开发针对整个G蛋白偶联受体类的新型口服小分子药物。该公司目前正在进行一项针对罕见内分泌疾病甲状旁腺功能低下患者的i期试验，预计将于2025年中期获得顶线数据。该公司截至2024年6月30日的12个月收入为100万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SEPN","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477809590","title":"GPCR药物开发商Septerna(SEPN.US)拟IPO筹资1.75亿美元 估值超6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477809590","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2477809590?lang=zh_cn&edition=full","pubTime":"2024-10-22 15:59","pubTimestamp":1729583976,"startTime":"0","endTime":"0","summary":"智通财经获悉，生物技术公司Septerna周一宣布了其IPO条款，该公司专注于开发针对整个G蛋白偶联受体类的新型口服小分子药物。这家总部位于加州南旧金山的公司计划以每股15美元至17美元的价格发行1090万股股票，筹资1.75亿美元。按照拟议定价区间的中点计算，Septerna完全稀释后的市值将达到6.26亿美元。Septerna正在开发靶向GPCR的口服小分子药物。Septerna成立于2019年，截至2024年6月30日的12个月收入为100万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SEPN","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.septerna.com","stockEarnings":[{"period":"1week","weight":-0.0833},{"period":"1month","weight":0.2242},{"period":"3month","weight":0.3222},{"period":"6month","weight":0.3511},{"period":"1year","weight":2.3795},{"period":"ytd","weight":0.4534}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Septerna, Inc.于2019年12月在特拉华州注册成立，名称为GPCR NewCo, Inc.。2021年6月，他们更名为Septerna, Inc.。该公司是一家临床阶段的生物技术公司，开创了G蛋白偶联受体（GPCR）口服小分子药物发现的新时代，其动力来自其专有的Native Complex PlatformTM。他们的工业规模平台旨在释放GPCR疗法的全部潜力，并发现和开发其深度候选产品管道，最初专注于治疗三个治疗领域的患者：内分泌学、免疫学和炎症，以及代谢疾病。","exchange":"NASDAQ","name":"Septerna, Inc.","nameEN":"Septerna, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Septerna, Inc.(SEPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Septerna, Inc.(SEPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Septerna, Inc.,SEPN,Septerna, Inc.股票,Septerna, Inc.股票老虎,Septerna, Inc.股票老虎国际,Septerna, Inc.行情,Septerna, Inc.股票行情,Septerna, Inc.股价,Septerna, Inc.股市,Septerna, Inc.股票价格,Septerna, Inc.股票交易,Septerna, Inc.股票购买,Septerna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Septerna, Inc.(SEPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Septerna, Inc.(SEPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}